Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001877 · ClinicalTrials.gov registry record · Phase 2
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
A Phase 2 study of Pulmonary Sarcoidosis, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00001877 is a Phase 2 study of Pulmonary Sarcoidosis that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 100 participants, below the 795-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001877, a Phase 2 study of Pulmonary Sarcoidosis, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Sarcoidosis is a disease most commonly affecting the lungs, but it can also involve lymph nodes, skin, liver, spleen, eyes, bones, and glands. The cause of the disease is unknown. When it occurs it can produce an inflammatory reaction leading to irreversible organ damage and disability. In sarcoidosis granulomas can form in various organs (primarily lung) which can lead to its dysfunction. Granuloma is formed by clusters of inflammatory cells. The formation of these granulomas is influenced by the release of a substance called TNF-alpha (tumor necrosis factor alpha) which is found in some white blood cells. A drug known as pentoxifylline (POF) is known to markedly reduce the release of TNF-alpha. The standard medical treatment for sarcoidosis is steroid therapy. However, steroid therapy is associated with significant side effects and often must be stopped. Unfortunately, some of these patients can relapse when the steroid therapy is discontinued. Because of this, researchers are interested in finding alternative therapies for the treatment of sarcoidosis. This study will evaluate the effectiveness of giving POF to patients with sarcoidosis currently taking steroids. Researchers will compare the results between patients taking steroids with pentoxifylline and those patients taking steroids alone.
Conditions Studied
Interventions
- DRUG Pentoxifylline
Study Locations (1)
Maryland
- National Heart, Lung and Blood Institute (NHLBI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 1999-02 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001877
The ClinicalTrials.gov registry entry for NCT00001877 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 795-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (87% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Pentoxifylline is the first listed.
NCT00001877 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001877 about?
NCT00001877 is a clinical study titled "Treatment of Pulmonary Sarcoidosis With Pentoxifylline". Sarcoidosis is a disease most commonly affecting the lungs, but it can also involve lymph nodes, skin, liver, spleen, eyes, bones, and glands. The cause of the disease is unknown. When it occurs it can produce an inflammatory reaction leading to irreversible organ damage and disability. In sarcoido...
What is the current status of trial NCT00001877?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 1999-02. Estimated completion is 2004-05.
What conditions does trial NCT00001877 study?
This clinical trial studies the following conditions: Pulmonary Sarcoidosis.
What interventions are being tested in trial NCT00001877?
The interventions under investigation include: Pentoxifylline (DRUG).
Who is sponsoring clinical trial NCT00001877?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001877 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RECRUITING · Phase 2
-
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
RECRUITING · Phase 1
-
Role of Genetic Factors in the Development of Lung Disease
RECRUITING
-
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
ACTIVE NOT RECRUITING · Phase 3
-
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.